 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. News Johnson & Johnson Unit Submits HIV Drug Candidate to FDA for ApprovalJuly 20, 2007 On Wednesday, Johnson & Johnson's Tibotec Pharmaceuticals Ltd. division said it had filed a new application for Food and Drug Administration approval of TMC125 (etravirine), its new HIV drug candidate. FDA's decision to fast-track TMC125 means the company can submit data as it becomes available, rather than all at once. The treatment for people infected with HIV-1 is meant to be administered with other antiretrovirals. Associated Press 07.18.2007  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
